These drugs could fight against BA.2 Omicron variant effectively

Credit: CC0 Public Domain

Scientists from the University of Wisconsin-Madison found the antiviral therapies remdesivir, molnupiravir, and the active ingredient in Pfizer’s Paxlovid pill (nirmatrelvir), remain effective against the BA.2 variant of SARS-CoV-2, the virus that causes COVID-19.

The research is published in the New England Journal of Medicine and was conducted by Yoshihiro Kawaoka et al.

The BA.2 Omicron variant is related to the more common BA.1 Omicron virus, and some evidence suggests that BA.2 can spread more quickly than the already highly contagious BA.1 variant.

In the study, the team tested seven monoclonal antibodies, three combinations of antibodies, and three antiviral treatments against the BA.2 variant.

Most clinically approved antibody treatments are a combination of multiple antibodies.

The intravenous drug remdesivir and the active ingredients in two anti-COVID-19 pills, Paxlovid and Merck’s molnupiravir, were nearly as effective against BA.1 as they are against the original strain of SARS-CoV-2.

The most effective antibody treatment against the BA.2 variant was Evusheld, which is approved in the U.S. to help prevent COVID-19 infection in people vulnerable to severe disease.

The antibodies sold by Regeneron and GlaxoSmithKline were much more effective against BA.2 than they are against the BA.1 Omicron variant, although they were not as potent against BA.2 as they are against earlier versions of the virus.

Available anti-COVID treatments are typically less effective against new variants than they are against the original virus strain, because they were designed and tested against earlier versions of the virus.

The BA.2 variant also remains susceptible to at least some of the monoclonal antibodies used to treat COVID-19, such as Evusheld by AstraZeneca.

Other antibody treatments were less effective against BA.2 than they are against earlier strains of SARS-COV-2.

The team says the bottom line is researchers have antibodies that appear to be more effective against BA. 2 compared with BA.1 or BA.1.1.

If you care about COVID, please read studies that COVID-19 vaccine protection fades within 6 months, and this drug is effective in treating severe COVID-19.

For more information about COVID, please see recent studies about new way to prevent broad range of COVID-19 variants, and results showing green tea offers new hope to beat COVID-19.

Copyright © 2022 Knowridge Science Report. All rights reserved.